Top entities: Qiagen, Kirby McInerney LLP, Lauren Molinaro, United States — New York.

What category does this event fall under?

Regulatory — classified as securities investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Kirby McInerney LLP continues investigation Qiagen · Qiagen declined · Qiagen released earnings

Is this event still developing?

This is an active story, last updated May 22, 2026. Coverage continues to evolve.

Regulatory securities investigation

Kirby McInerney LLP investigates Qiagen

Q: When did this event occur?

First reported May 19, 2026; last updated May 22, 2026.

Q: What is the market impact?

Direct. The market is negatively impacted by the decline in Qiagen>>>'s stock price and the ongoing investigation, which suggests potential financial misconduct.

Analysis based on 6 articles · First reported May 19, 2026 · Last updated May 22, 2026

Sentiment

-40

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the decline in Qiagen>>>'s stock price and the ongoing investigation, which suggests potential financial misconduct. This could lead to further volatility for Qiagen>>> shares and potentially impact investor confidence in the biotechnology sector.

biotechnology legal services

Event Summary

The law firm Kirby McInerney LLP>>> is investigating Qiagen>>> for possible violations of federal securities laws and unlawful business practices. This follows Qiagen>>>'s announcement of preliminary first-quarter 2026 results on April 27, 2026, which showed a 1% decline in net sales and a 5% decline in sales of its QuantiFERON product on a constant exchange rate basis. This news caused Qiagen>>>'s share price to drop by approximately 11%, or $4.07 per share, from $38.09 to $34.02. Previously, on February 5, 2026, Qiagen>>> had released fourth-quarter 2025 earnings, projecting 6-7% growth for QuantiFERON in 2026, a forecast that now appears to be contradicted by the Q1 2026 results. The investigation is ongoing, and no lawsuit has been filed yet.

Key Actions

100 Kirby McInerney LLP continues investigation Qiagen

95 Qiagen declined

90 Qiagen released earnings

Entities Involved

stock

Qiagen

The company's stock price declined significantly after announcing lower-than-expected sales for its QuantiFERON product, leading to an investigation into possible securities law violations.

Importance 100 Sentiment -50

priv

Kirby McInerney LLP

This law firm is conducting an investigation on behalf of Qiagen>>> investors concerning potential violations of federal securities laws by Qiagen>>> and its senior management.

Importance 80 Sentiment 20

per

Lauren Molinaro

Lauren Molinaro is a contact person at Kirby McInerney LLP>>> for investors interested in the investigation against Qiagen>>>.

Importance 30 Sentiment 0

loc

United States — New York

United States — New York is the location where Kirby McInerney LLP>>> is based.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard